End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31.96 CNY | -1.51% | +1.95% | +6.93% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.89 for the current period. Therefore, the company is undervalued.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.93% | 2.62B | C+ | ||
-11.48% | 3.7B | D+ | ||
-0.15% | 3.37B | D- | ||
-23.85% | 3.11B | D | ||
+9.62% | 2.81B | - | ||
+9.95% | 1.38B | - | - | |
-20.17% | 983M | - | ||
-39.70% | 680M | - | - | |
-0.53% | 454M | - | D+ | |
-0.38% | 383M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603883 Stock
- Ratings LBX Pharmacy Chain